A Possible Protective Effect of IgA Against Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) in Bronchoalveolar Lavage in COVID-19 Patients Admitted to Intensive Care Unit.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI

COVID-19*/immunology ; COVID-19*/prevention & control ; Immunoglobulin A*/analysis ; Immunoglobulin A*/blood ; Immunoglobulin A*/immunology ; SARS-CoV-2*/immunology ; Antibodies, Viral*/blood ; Antibodies, Viral*/immunology ; Immunoglobulin G*/blood ; Immunoglobulin G*/immunology ; Intensive Care Units* ; Bronchoalveolar Lavage Fluid*/virology ; Bronchoalveolar Lavage Fluid*/immunology; Humans ; Female ; Male ; Middle Aged ; Aged ; Adult ; Aged, 80 and over

SARS-CoV-2 infection induces a humoral immune response, producing virus-specific antibodies such as IgM, IgG, and IgA. IgA antibodies are present at mucosal sites, protecting against respiratory and other mucosal infections, including SARS-CoV-2, by neutralizing viruses or impeding attachment to epithelial cells. Since SARS-CoV-2 spreads through the nasopharynx, the specific IgAs of SARS-CoV-2 are produced quickly after infection, effectively contributing to virus neutralization. Dimeric IgA has been reported to be 10 to 15 times more potent than its equivalent IgG, suggesting that this isotype may be particularly interesting in developing new monoclonal antibodies and/or new vaccines efficiently neutralizing the virus at the mucosal sites. It is still unclear whether IgA antibodies in BAL might play a role in the disease course and if their presence may have a prognostic significance. However, a harmful effect on diseases with high IgA titers has been reported. This study evaluated mucosal-specific IgA and IgG profiles in BAL of patients with COVID-19 acute respiratory failure admitted to the ICU. We included 57 patients (41 males and 16 females), admitted to the ICU of the University of Foggia. We used a commercially available ELISA assay to evaluate the presence of SARS-CoV-2 IgG and IgA antibodies in plasma and BAL of the 57 hospitalized patients with severe COVID-19 respiratory failure. However, 40/57 BAL and plasma from infected patients were available for the ELISA test; the remaining specimens were unsuitable. IgG and IgA antibodies against SARS-CoV-2 were detectable in 37 (92.5%) and 40 (100%) plasma specimens, respectively. IgG antibodies were found in a single sample, while IgAs were detected in 19 of 40 BAL samples analyzed. Correlations between these parameters and patient outcomes reveal a signature associated with survival. Interestingly, a statistically significant inverse correlation was found between the mortality rate and the presence of IgA to SARS-CoV-2 in BAL specimens. None of the 19 patients with a positive IgA died, compared to 7 out of 12 patients with a negative IgA-BAL ( p : <0.0004). Despite being limited in size, this study suggests a significant protective effect of mucosal immunity in COVID-19 patients, even in advanced disease stages, and a role of IgA in the defense against the virus, as well as the possible use of effective vaccines and therapeutic strategies based on IgA antibodies.

Eur Respir J. 2020 Aug 27;56(2):. (PMID: 32398307)
Front Immunol. 2023 Mar 27;14:1127339. (PMID: 37051237)
Vaccines (Basel). 2023 Feb 12;11(2):. (PMID: 36851295)
Nat Rev Drug Discov. 2022 Sep;21(9):676-696. (PMID: 35725925)
MAbs. 2011 Jul-Aug;3(4):352-61. (PMID: 21691145)
Mol Ther. 2024 Mar 6;32(3):689-703. (PMID: 38268188)
Nat Commun. 2020 Aug 21;11(1):4198. (PMID: 32826914)
Crit Care Med. 1985 Oct;13(10):818-29. (PMID: 3928249)
Immunity. 2011 Feb 25;34(2):269-80. (PMID: 21315623)
Front Immunol. 2021 Jan 28;11:618685. (PMID: 33584712)
Front Immunol. 2022 Sep 29;13:842468. (PMID: 36248831)
Mucosal Immunol. 2011 Nov;4(6):590-7. (PMID: 21937984)
Immunol Rev. 2021 Sep;303(1):83-102. (PMID: 34331314)
J Med Virol. 2021 Sep;93(9):5409-5415. (PMID: 33932299)
Heliyon. 2024 Jan 03;10(1):e24031. (PMID: 38230244)
Vaccines (Basel). 2023 Oct 27;11(11):. (PMID: 38005979)
Intensive Care Med. 1996 Jul;22(7):707-10. (PMID: 8844239)
Jpn J Infect Dis. 2022 May 24;75(3):228-233. (PMID: 34588364)
Vaccines (Basel). 2023 Sep 07;11(9):. (PMID: 37766138)
J Allergy Clin Immunol Pract. 2023 Jun;11(6):1936-1938. (PMID: 36858279)
Front Immunol. 2013 Aug 06;4:222. (PMID: 23964273)
Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1092-8. (PMID: 9351607)
PLoS Pathog. 2020 Dec 14;16(12):e1009103. (PMID: 33315937)
PLoS One. 2019 Jul 22;14(7):e0220196. (PMID: 31329652)
PLoS One. 2021 Jun 23;16(6):e0252317. (PMID: 34161348)
Clin Chim Acta. 2020 Aug;507:164-166. (PMID: 32343948)
Sci Transl Med. 2021 Jan 20;13(577):. (PMID: 33288662)
Lancet Respir Med. 2022 Apr;10(4):392-402. (PMID: 35114141)
Sci Transl Med. 2021 Jan 20;13(577):. (PMID: 33288661)
Transfusion. 2021 Jun;61(6):1740-1748. (PMID: 34041759)
Cell Rep. 2021 Mar 2;34(9):108790. (PMID: 33596407)
Sci Rep. 2022 Sep 02;12(1):14932. (PMID: 36056118)
Antibodies (Basel). 2019 Dec 05;8(4):. (PMID: 31817406)

n. 341/2022 NextGenerationUE as part of PNRR MUR - M4C2 - Investimento 1.3 - Public Call "Partenariati Estesi" - D.D. n. 341/2022."

Keywords: APACHE II score; SARS-CoV-2; SOFA score; anti-SARS-CoV-2 IgA; anti-SARS-CoV-2 IgG; bronchoalveolar lavage (BAL)

0 (Immunoglobulin A)
0 (Antibodies, Viral)
0 (Immunoglobulin G)

Date Created: 20250108 Date Completed: 20250108 Latest Revision: 20250108

20250110

PMC11680283

10.3390/v16121851

39772161